Tagged with EG

clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital.     In the past ten…

regulation The executive director of the board bringing together multinational and local drug manufacturers talks about the chamber’s goal to position the pharmaceutical industry as the most important manufacturing sector in Mexico, how the chamber is working with the government and its membership to reach this goal and which new dynamics are…

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

investment Newcomers to Algeria’s fledgling, but increasingly vibrant pharmaceuticals sector are immediately struck by the sense of liveliness pervading the industry. Indeed, as growth patterns in developed markets continue to flatten, and the protagonists of ‘big pharma’ pivot towards securing new revenue sources in emergent economies, Algeria must surely constitute one…

consumer healthcare GSK’s Consumer Healthcare’s regional manager for the southern cone discusses the countries longstanding commitment to the Argentinian consumer and how this history allows them to succeed in a country typically dominated by strong domestic brands.   There was recently a wave of M&A in Chile and elsewhere, do you see this…

distribution The Argentinian healthcare system is subject to rules, in which delivery agreements for medicines to health insurance agents undergo health funders guidelines and other regulations imposed by the Superintendency of Health Services Office. Dr. Raúl Pistorio, Executive Director of Farmalink, the company responsible for this process, discusses this peculiar regulatory arrangement.…

regulation Carlos Chiale, National Administrator of ANMAT, discusses the agency’s latest strategy implementation and its pioneering work in the area of fighting drug falsification.   Could you provide a historical overview of ANMAT, its main achievements and current activities today? Since its creation in 1992, ANMAT has performed activities intended for…

doctors MMA’s president shares the reasons why Malaysia is ranked today third in terms of healthcare quality, with a very efficient public system, high quality doctors and strong government support. However, the situation could change as too many doctors change to the private sector, NCDs are drastically increasing and financing healthcare…

IMS IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also shares the opportunities present for pharma companies to invest in Malaysia.     IMS is now providing data for the…

generics Chile is aiming to achieve complete bioequivalence of generics by the end of 2014. Chile’s Public Health Institute is leading the bioequivalence testing, aimed at regulating differences between generic and bioequivalent drugs. The recently appointed director of the Public Health Institute, Ricardo Fabrega, echoes the need for drastic change and…